Search

Your search keyword '"Bühnen, Ina"' showing total 8 results
Start Over Author "Bühnen, Ina" Search Limiters Full Text
8 results on '"Bühnen, Ina"'

2. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., Bühnen, Ina, Plütschow, Annette, Kobe, Carsten, Dietlein, Markus, Wendtner, Clemens‐Martin, Thorspecken, Sven, Topp, Max S., Mauser, Mareike, von Tresckow, Bastian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, and Tresckow, Bastian

Subjects
Cancer Research, Oncology, Medizin, Hematology, General Medicine
Published
2022

3. Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Bühnen, Ina, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Herhaus, Peter, additional, Halbsguth, Teresa V, additional, Schaub, Valdete, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Bormann, Matthias, additional, Dickhut, Andreas, additional, Kaul, Helen, additional, Fuchs, Michael, additional, Kobe, Carsten, additional, Baues, Christian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2022
Full Text
View/download PDF

4. P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

Author

Voltin, Conrad-Amadeus, primary, Kreissl, Stefanie, additional, Kaul, Helen, additional, Bühnen, Ina, additional, Mettler, Jasmin, additional, Pabst, Thomas, additional, Eichenauer, Dennis A., additional, Fuchs, Michael, additional, Diehl, Volker, additional, Dietlein, Markus, additional, Engert, Andreas, additional, Borchmann, Peter, additional, and Kobe, Carsten, additional

Published
2022
Full Text
View/download PDF

5. T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

Author

Eichenauer, Dennis A., primary, Bühnen, Ina, additional, Fuchs, Michael, additional, Greil, Richard, additional, Moccia, Alden, additional, Zijlstra, Josée. M., additional, Hartmann, Sylvia, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2022
Full Text
View/download PDF

6. Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann-Grill, Karolin, additional, Kobbe, Guido, additional, Wilhelm, Martin, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William Hermann, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch-Ulrich, Kathleen, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J, additional

Published
2021
Full Text
View/download PDF

8. Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Author

Bröckelmann, Paul J, Bühnen, Ina, Herhaus, Peter, Meissner, Julia, Trautmann-Grill, Karolin, Müller, Horst, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas, and Behringer, Karolin

Abstract

Background: First-line treatment of patients with classical Hodgkin lymphoma (HL) with anti-PD1 antibodies in combination with AVD chemotherapy is highly effective across risk-groups. Based on encouraging phase II and ongoing phase III trials, anti-PD1 based first-line treatment may hence soon become a first-line treatment option. To date, no data on fertility and gonadal function after anti-PD1 based first-line HL treatment is available. Herein, we present data on pregnancies and gonadal function in patients treated within the randomized GHSG phase II NIVAHL trial.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results